ArticleHereditas2025
The bibliometric analysis of research on traditional Chinese medicine regulating gut microbiota for cancer treatment from 2014 to 2024.
Article in Hereditas, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe modulation of gut microbiota by Traditional Chinese Medicine (TCM) offers a promising approach to cancer treatment. However, a comprehensive bibliometric evaluation of this emerging field is lacking.
objectiveThis study aimed to systematically analyze global research trends, hotspots, and future directions related to TCM regulation of gut microbiota in cancer therapy from 2014 to 2024.
methodsPublications were retrieved from the Web of Science Core Collection. Bibliometric and visual analyses were conducted using VOSviewer and CiteSpace to examine publication trends, country and institutional collaborations, core authors and journals, keyword co-occurrence, and research frontiers.
resultsA total of 340 relevant articles were identified. The number of publications increased significantly after 2018, indicating growing interest in this field. China dominated the research landscape, both in productivity and institutional collaboration. Core research hotspots included "short-chain fatty acids," "tumor microenvironment," "apoptosis," and "immune response." Thematic evolution analysis highlighted a shift from general gut microbiota research to precise molecular mechanisms and targeted regulation. Emerging topics such as "metabolomics" and "immune checkpoint blockade" suggest future directions.
conclusionThis study provides a comprehensive overview of the current research landscape on TCM-modulated gut microbiota in cancer treatment. By identifying core contributors, research hotspots, and frontiers, it offers valuable guidance for future investigations and interdisciplinary collaborations in this promising field.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.